Inés Patricia Jara Tapia

Inés Patricia Jara Tapia

Auto-generated profile, based on publicly available information

Inés Patricia Jara Tapia

Universidad Central del Ecuador, Medical Department. Quito - Ecuador

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Ibero-American Journal of Health Science Research
Verified
Journal Article
Open access
PDF file
DADiana Lorena Pedrosa Astudillo
Diana Lorena Pedrosa Astudillo
ITInés Patricia Jara Tapia
Inés Patricia Jara Tapia
LGLizbeth Carolina López García
Lizbeth Carolina López García
TSTiffany Ivanna Guerrero Solorzano
Tiffany Ivanna Guerrero Solorzano
AHAlberto Fabián Corral Chang Huang
Alberto Fabián Corral Chang Huang
DCDenise Isabel Guevara Cando
Denise Isabel Guevara Cando
Hypothyroidism, which is developed in 4-10 % of the population, and subclinical hypothyroidism found in more than 10 % of people which are highly associated with cardiovascular pathophysiology at some level. Hypothyroidism, which is the most frequent endocrine disorder with a lack of enough thyroid hormones, presents a wide range of cardiovascular complications, including coronary artery disease, heart failure, and dyslipidemia. Thyroid hormone replacement therapy, particularly levothyroxine (LT4), continues to be the central management of hypothyroidism, which aims to restore euthyroidism and other cardiac comorbidities as well as relieving symptoms. Nonetheless, the complex interworking of thyroid function and cardiovascular health requires a detailed clarification of the processes associated with disease development and drug therapy. Hypothyroidism triggers a chain of cardiovascular alterations such as aberrant lipid metabolism, endothelial dysfunction, and lessened cardiac contractility primarily by lowering the thyroid hormone level. Besides, these modifications eventually lead to raised rates of atherosclerosis, myocardial infarction, and heart failure. LT4 replacement therapy achieves normalization of hyperthyroidism with the replacement of thyroid hormone deficiency, which restores the cardiovascular system to normal by doing so. LT4 modulates lipid metabolism, improves endothelial function, and stimulates myocardial contractility via several different mechanisms. LT4 therapy acts on systemic inflammation and oxidation to accentuate the protective effects of the cardiovascular system. Apart from this, there is an increasing awareness about the use of new thyroid hormone formulations, like LH4, in the therapy of hypothyroidism. LH4, the thyromimetic compound, demonstrated a similar binding affinity at the thyroid hormone receptor as T3 (triiodothyronine) but with better tissue selectivity and more metabolic stability. Clinical trials have proven the potency of LH4 in lowering symptoms of hypothyroidism, for example, fatigue, weight gain which are leading cause of cardiovascular disorders. LH4 administration has been safe for up to six months, and only mild adverse effects have been reported when it is used more than a year.

21 June 2025 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
ITInés Patricia Jara Tapia
Inés Patricia Jara Tapia
CMCarol Alexandra Sánchez Martínez
Carol Alexandra Sánchez Martínez
MMManuel Alejandro Reyes Muñoz
Manuel Alejandro Reyes Muñoz
XVXavier Andrés Fernández Vélez
Xavier Andrés Fernández Vélez
ECElías Joel Loaiza Cevallos
Elías Joel Loaiza Cevallos
NJNubia Estefani Ardila Jalilie
Nubia Estefani Ardila Jalilie
Introduction: patients with critical comorbidities undergoing major abdominal surgery face elevated risks of complications due to reduced physiological reserve. Hemodynamic and metabolic optimization strategies, including goal-directed fluid therapy and glycemic or nutritional protocols, may improve perioperative outcomes. This systematic review evaluates the effectiveness of such interventions in high-risk patients.Methodology: a systematic search was performed in PubMed, Google Scholar and Cochrane Library up to May 2025. Eligible studies included randomized controlled trials and cohort observational studies. Risk of bias was assessed using the Cochrane RoB 2.0 tool for RCTs and the Newcastle–Ottawa Scale for observational studies. Two reviewers independently screened and extracted data.Results: seventeen studies evaluated hemodynamic and metabolic optimization in high-risk abdominal surgery. Hemodynamic strategies—such as goal-directed fluid therapy guided by cardiac index or stroke volume variation—were associated with reductions in 30-day mortality (15.5% vs. 21.8%, p=0.005), complications, ICU admissions, and length of stay in several trials. However, outcomes were inconsistent across studies, with some showing no significant benefits. Metabolic optimization, including glycemic control and individualized nutrition, improved nitrogen balance, body composition, glycemic targets, and reduced liver dysfunction. Malnutrition was linked to increased complications and prolonged hospital stay. While many interventions showed promising results, variability in study designs and outcomes limits definitive conclusions.Conclusion: hemodynamic and metabolic optimization may improve outcomes in high-risk abdominal surgery, though effects vary. Multimodal strategies targeting fluid balance, glycemic control, and nutrition appear beneficial.